Article
Biochemistry & Molecular Biology
Jiahao Chen, Jingxin Liu, Pengguihang Zeng, Cai Zhao, Xinyi Liu, Jun Sun, Jia Wang, Peihang Fang, Wenjie Chen, Junjun Ding
Summary: Estrogen (E2) and BRCA1 deficiency synergistically induce DNA damage in breast cancer cells, possibly involving transcriptional activation of ER genes and changes in DNA damage distribution.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2022)
Article
Endocrinology & Metabolism
Bassem Refaat, Akhmed Aslam, Shakir Idris, Ahmed H. Almalki, Mofareh Y. Alkhaldi, Hassan A. Asiri, Riyad A. Almaimani, Abdulrahman Mujalli, Faisal Minshawi, Sara A. Alamri, Mona I. AlHussain, Badee A. Baltow, Mansour H. Alqasmi, Ghaiyda T. Basfar, Ohoud M. Alosaimi, Ibrahim A. Muhayya
Summary: This study reveals that the expression of estrogen and androgen receptors in colorectal cancer tissues is correlated with tumor characteristics, and hormonal therapy may serve as an alternative treatment strategy for colorectal cancer.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Medicine, General & Internal
Geriolda Topi, Souvik Ghatak, Shakti Ranjan Satapathy, Roy Ehrnstrom, Marie-Louise Lydrup, Anita Sjolander
Summary: This study investigated the combined role of estrogen receptor alpha (ERα) and beta (ERβ) expression in the prognosis of female patients with colorectal cancer (CRC). The results showed that high ERβ and low ERα expression correlated with a better prognosis and higher expression of antitumorigenic proteins. The study suggests that the combined expression of ERα and ERβ could be used as a predictive marker for CRC patients, especially for predicting disease-free survival.
FRONTIERS IN MEDICINE
(2022)
Article
Oncology
Kathryn P. Lowry, Laura Ichikawa, Rebecca A. Hubbard, Diana S. M. Buist, Erin J. A. Bowles, Louise M. Henderson, Karla Kerlikowske, Jennifer M. Specht, Brian L. Sprague, Karen J. Wernli, Janie M. Lee
Summary: In women with previously treated breast cancer, the risk of second breast cancers is higher in those with ER-negative primary cancer during the first 5 years after diagnosis compared to those with ER-positive cancer.
Article
Biochemistry & Molecular Biology
Agnieszka Anna Rawluszko-Wieczorek, Julia Lipowicz, Marta Nowacka, Kamila Ostrowska, Paulina Pietras, Malgorzata Blatkiewicz, Marcin Rucinski, Pawel Piotr Jagodzinski, Michal Nowicki
Summary: The presence of estrogen receptor beta (ER beta) is inversely correlated with the occurrence of colorectal cancer (CRC), and low expression of ER beta is associated with poorer overall survival of CRC patients. ER beta can inhibit tumorigenesis through various molecular pathways and also has an impact on the hypoxic response in CRC cells.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
(2024)
Article
Biology
Tommaso De Marchi, Paul Theodor Pyl, Martin Sjostrom, Susanne Erika Reinsbach, Sebastian DiLorenzo, Bjorn Nystedt, Lena Tran, Gyula Pekar, Fredrik Warnberg, Irma Fredriksson, Per Malmstrom, Marten Ferno, Lars Malmstrom, Johan Malmstom, Emma Nimeus
Summary: A proteogenomic analysis of matching primary breast cancer and ipsilateral breast tumor recurrence (IBTR) samples provides insight into the development of IBTR and may be useful in identifying biomarkers for IBTR formation.
COMMUNICATIONS BIOLOGY
(2023)
Editorial Material
Biochemistry & Molecular Biology
Madhulika Tripathi, Brijesh Kumar Singh
Summary: Orphan nuclear receptor estrogen-related receptor alpha (ERR alpha) plays a crucial role in regulating energy metabolism, but its hyperactivation in breast cancer leads to cell migration, proliferation, and tumour development. The study by Brindisi et al. reveals that cholesterol can activate ERR alpha endogenously, promoting breast cancer aggressiveness, highlighting the potential anti-tumour effects of cholesterol-lowering drugs like statins.
Article
Cell Biology
Harmit S. Ranhotra
Summary: In this article, we review the latest research on the influence of ERR alpha on host metabolism and biology, particularly cancer. This receptor plays a crucial role in energy metabolism and gene regulation, interacts with numerous transcription factors and signaling pathways, and has significant regulatory effects on health and disease.
MOLECULAR AND CELLULAR BIOCHEMISTRY
(2022)
Article
Cell Biology
Yuejiao Zhong, Kang He, Lin Shi, Lingxiang Chen, Bin Zhou, Rong Ma, Hui Yu, Jia Zhang, You Shuai, Yan Fei, Jianwei Lu
Summary: This study found that ERR alpha is highly expressed in gastric cancer tissues and is significantly correlated with TNM staging and patient survival. Downregulation of ERR alpha can inhibit cell invasion and migration, making it a potential diagnostic marker for gastric cancer.
Article
Oncology
Yavuz Mert Aydin, Ahmet Bilgehan Sahin, Rabia Dolek, Berna Aytac Vuruskan, Gokhan Ocakoglu, Hakan Vuruskan, Ismet Yavascaoglu, Burhan Coskun
Summary: This study aimed to investigate the impact of estrogen receptor-alpha (ER alpha) and estrogen receptor-beta (ER beta) on biochemical recurrence (BCR) of non-metastatic prostate cancer (PCa) after surgery. The results showed that patients with ER alpha(-)/ER beta(+) staining had a lower BCR rate and better prognosis.
Article
Oncology
Reema S. Wahdan-Alaswad, Susan M. Edgerton, Hiba Salem, Hyun Min Kim, Aik Choon Tan, Jessica Finlay-Schultz, Elizabeth A. Wellberg, Carol A. Sartorius, Britta M. Jacobsen, Bryan R. Haugen, Bolin Liu, Ann D. Thor
Summary: The study revealed clinically significant adverse interactions between THRT, estrogenic, and oncogenic signaling in patients with steroid receptor-positive, lymph node-negative breast cancer.
CLINICAL CANCER RESEARCH
(2021)
Review
Endocrinology & Metabolism
Xue-Ling Xu, Zheng-Yuan Huang, Kun Yu, Jun Li, Xiang-Wei Fu, Shou-Long Deng
Summary: This review focuses on the role of ER alpha and ER beta in polycystic ovary syndrome (PCOS), ovarian cancer, and premature ovarian failure (POF), as well as the major challenges of existing therapies. It provides a reference for the treatment of estrogen target tissue ovarian diseases.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Oncology
Mohan Li, Yuelun Zhang, Lijian Pei, Zhiyong Zhang, Gang Tan, Yuguang Huang
Summary: This study found that the effects of early recurrence after breast cancer surgery were similar between regional anesthesia-analgesia and general anesthesia in both ER-negative and ER-positive patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Cell Biology
Zhiguo Niu, Jianing Fan, Fengzhe Chen, Huijie Yang, Xin Li, Ting Zhuang, Chunlei Guo, Qi Cao, Jian Zhu, Hui Wang, Qingsong Huang
Summary: Breast cancer is the most common malignancy in women globally. Abnormal expression of RBCK1 protein in breast tumors makes it a valuable diagnostic marker and drug target. Hypoxic regions in breast cancer activate the HIF1 pathway, influencing tumor recurrence and metastasis. Targeting RBCK1 could be a promising treatment strategy for ER-positive breast cancer.
CELL DEATH & DISEASE
(2022)
Article
Oncology
Jose P. Leone, Bernardo A. Leone, Nabihah Tayob, Michael J. Hassett, Julieta Leone, Rachel A. Freedman, Sara M. Tolaney, Eric P. Winer, Carlos T. Vallejo, Nancy U. Lin
Summary: The study aimed to investigate the 20-year risk of breast cancer-specific mortality in stage III breast cancer patients and found that the risk was significantly higher in HR-negative tumors compared to HR-positive tumors. The risk of BCSM conditional on having survived 5 years depended on various factors. Late BCSM was found to be associated with traditional clinicopathologic factors.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Jiazhang Wei, Jiaxiang Ye, Yue Luo, Jingjin Weng, Qian He, Fei Liu, Min Li, Yan Lin, Yongqiang Li, Zhe Zhang, Shenhong Qu, Jinyan Zhang
Article
Gastroenterology & Hepatology
Rong-yun Mai, Jie Zeng, Hua-ze Lu, Rong Liang, Yan Lin, Xue-min Piao, Xing Gao, Guo-bin Wu, Fei-xiang Wu, Liang Ma, Bang-de Xiang, Le-qun Li, Jia-zhou Ye
Summary: The combination of APRI and sFLR showed significantly greater predictive accuracy for severe PHLF in HCC patients compared to using CP grade, MELD, APRI, or sFLR alone.
JOURNAL OF GASTROINTESTINAL SURGERY
(2021)
Article
Surgery
Rong-yun Mai, Hua-ze Lu, Tao Bai, Rong Liang, Yan Lin, Liang Ma, Bang-de Xiang, Guo-bin Wu, Le-qun Li, Jia-zhou Ye
Article
Genetics & Heredity
Ziyu Liu, Yan Lin, Xing Gao, Rongyun Mai, Xuemin Piao, Jiazhou Ye, Rong Liang
FRONTIERS IN GENETICS
(2020)
Review
Biotechnology & Applied Microbiology
Yan Lin, Ziqin He, Jiazhou Ye, Ziyu Liu, Xiaomin She, Xing Gao, Rong Liang
ONCOTARGETS AND THERAPY
(2020)
Article
Oncology
Rong Liang, Jinyan Zhang, Zhihui Liu, Ziyu Liu, Qian Li, Xiaoling Luo, Yongqiang Li, Jiazhou Ye, Yan Lin
Summary: RBM8A is abnormally overexpressed in hepatocellular carcinoma (HCC) and is involved in the development of drug resistance. It has the ability to regulate tumor-related signaling pathways, particularly through its interaction with histone deacetylase 9 (HDAC9). These findings suggest that RBM8A and its related pathways could serve as potential markers of oxaliplatin resistance and therapeutic targets in HCC.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Min Luo, Yao Xiong, Yan Lin, Rong Liang, Yongqiang Li, Lianying Ge
Summary: The study found that HHLA2 is highly expressed in HCC tissues compared to para-carcinoma liver tissues, indicating its significant role in HCC development and progression. Due to its high expression, HHLA2 may serve as a potential prognostic biomarker for HCC.
MEDICAL SCIENCE MONITOR
(2021)
Article
Oncology
Rong-yun Mai, Jie Zeng, Wei-da Meng, Hua-ze Lu, Rong Liang, Yan Lin, Guo-bin Wu, Le-qun Li, Liang Ma, Jia-zhou Ye, Tao Bai
Summary: The study found that an artificial neural network model can predict PHER for HCC patients more accurately, aiding in determining postoperative treatment and monitoring.
Review
Oncology
Jiazhou Ye, Xiaomin She, Ziyu Liu, Ziqin He, Xing Gao, Lu Lu, Rong Liang, Yan Lin
Summary: EIF4A3 plays a crucial role in post-transcriptional gene regulation and maintains the expression of important proteins, but its overexpression is associated with tumorigenesis in various cancers. Further research is needed to elucidate its functions, mechanisms, and potential clinical applications, providing new insights and opportunities for cancer diagnosis and treatment.
FRONTIERS IN ONCOLOGY
(2021)
Article
Immunology
Min Luo, Yan Lin, Rong Liang, Yongqiang Li, Lianying Ge
Summary: Higher levels of HHLA2 in HCC are associated with advanced clinical cancer stage, multiple tumors, poor tumor differentiation, microvascular invasion, and hepatic capsule invasion. High levels of HHLA2 are correlated significantly with density of TILs, but not with PD-L1 levels. High HHLA2 levels are associated with worse prognosis.
JOURNAL OF INFLAMMATION RESEARCH
(2021)
Article
Oncology
Yan Lin, Lei Wei, Beiquan Hu, Jinyan Zhang, Jiazhang Wei, Zhongrun Qian, Donghua Zou
Summary: The study revealed that RBM8A is up-regulated in GBM tissues and its higher expression is correlated with worse prognosis. RBM8A may promote GBM cell proliferation and migration by activating the Notch/STAT3 pathway, suggesting it as a potential therapeutic target for GBM treatment.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Yue Luo, Jiaxiang Ye, Yayan Deng, Yujuan Huang, Xue Liu, Qian He, Yong Chen, Qiuyun Li, Yan Lin, Rong Liang, Yongqiang Li, Jiazhang Wei, Jinyan Zhang
Summary: The miRNA-185-5p/STIM1 axis regulates the invasiveness of nasopharyngeal carcinoma (NPC) cell lines by affecting EGFR activation, making it a potential therapeutic target. Additionally, knocking down STIM1 inhibits migration ability and locoregional lymphatic invasion of NPC cells.
Article
Oncology
Jiazhou Ye, Yan Lin, Xing Gao, Lu Lu, Xi Huang, Shilin Huang, Tao Bai, Guobin Wu, Xiaoling Luo, Yongqiang Li, Rong Liang
Summary: Bioinformatics tools were used to identify prognosis-related molecular subtypes and biomarkers of hepatocellular carcinoma (HCC). Differential expression analysis of four datasets identified 3330 overlapping differentially expressed genes (DEGs) in the same direction in all four datasets. Those genes were involved in the cell cycle, FOXO signaling pathway, as well as complement and coagulation cascades. Based on non-negative matrix decomposition, two molecular subtypes of HCC with different prognoses were identified, with subtype C2 showing better overall survival than subtype C1. Cox regression and Kaplan-Meier analysis showed that 217 of the overlapping DEGs were closely associated with HCC prognosis. The subset of those genes showing an area under the curve >0.80 was used to construct random survival forest and least absolute shrinkage and selection operator models, which identified seven feature genes (SORBS2, DHRS1, SLC16A2, RCL1, IGFALS, GNA14, and FANCI) that may be involved in HCC occurrence and prognosis. Based on the feature genes, risk score and recurrence models were constructed, while a univariate Cox model identified FANCI as a key gene involved mainly in the cell cycle, DNA replication, and mismatch repair. Further analysis showed that FANCI had two mutation sites and that its gene may undergo methylation. Single-sample gene set enrichment analysis showed that Th2 and T helper cells are significantly upregulated in HCC patients compared to controls. Our results identify FANCI as a potential prognostic biomarker for HCC.
Article
Oncology
Xing Gao, Cheng Lu, Ziyu Liu, Yan Lin, Julu Huang, Lu Lu, Shuanghang Li, Xi Huang, Minchao Tang, Shilin Huang, Ziqin He, Xiaomin She, Rong Liang, Jiazhou Ye
Summary: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. Sorafenib, a first-line chemotherapeutic drug, is the standard therapy for advanced HCC. However, the development of drug resistance limits its efficacy. This study aimed to identify the mechanisms underlying sorafenib resistance and found that the RBM38-GAS5 signaling pathway is involved.
Review
Oncology
Xue Liu, Yayan Deng, Yujuan Huang, Jiaxiang Ye, Sifang Xie, Qian He, Yong Chen, Yan Lin, Rong Liang, Jiazhang Wei, Yongqiang Li, Jinyan Zhang
Summary: Genomic instability plays a crucial role in driving the evolution of malignancies, enhancing tumor cells' ability to adapt to the tumor microenvironment. Nasopharyngeal carcinoma progression is driven by genomic instability and persistent EBV infection, highlighting the importance of understanding and targeting genomic instability for effective treatment strategies.
